Skip to main content
. 2022 Mar 31;13:843515. doi: 10.3389/fimmu.2022.843515

Figure 3.

Figure 3

Evaluation and validation of the utility of FMI in training set and validation sets. (A) Distribution of the patients’ normalized FMI score. (B) Patients’ overall survival time along with their FMI score. (C) K-M analyses of OS between high- and low-FMI groups. (D) K-M analyses of DFS, DSS, and PFS between high- and low-FMI groups in training set. FMI, fatty acid metabolism index; K-M, Kaplan–Meier; OS, overall survival; DFS, disease-free survival; DSS, disease-specific survival; PFS, progression-free survival.